Amgen Inc. (NASDAQ:AMGN) Shares Bought by Imprint Wealth LLC

Imprint Wealth LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 41.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,411 shares of the medical research company’s stock after acquiring an additional 416 shares during the quarter. Imprint Wealth LLC’s holdings in Amgen were worth $416,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Briaud Financial Planning Inc bought a new position in Amgen during the 3rd quarter worth approximately $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen in the 4th quarter worth approximately $29,000. OFI Invest Asset Management acquired a new stake in Amgen in the 3rd quarter valued at approximately $26,000. Planned Solutions Inc. acquired a new position in shares of Amgen during the 4th quarter valued at $30,000. Finally, Providence Capital Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter worth $30,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $295.30.

Amgen Price Performance

Shares of NASDAQ AMGN traded down $0.57 on Tuesday, hitting $264.94. The company’s stock had a trading volume of 579,238 shares, compared to its average volume of 2,851,632. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market capitalization of $141.99 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58. The stock has a 50 day moving average of $279.63 and a 200-day moving average of $281.52. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.09 earnings per share. As a group, research analysts predict that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.40%. Amgen’s payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.